MIRTAZAPINE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	MIRTAZAPINE	mirtazapine	TABLET, ORALLY DISINTEGRATING;ORAL	077376	ANDA	Cardinal Health 107, LLC	55154-8335-6	1 BLISTER PACK in 1 BAG (55154-8335-6) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2005-12-08
Aurobindo Pharma	MIRTAZAPINE	mirtazapine	TABLET, ORALLY DISINTEGRATING;ORAL	077376	ANDA	Rising Pharma Holdings, Inc.	57237-011-06	5 BLISTER PACK in 1 CARTON (57237-011-06) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2005-12-08
Aurobindo Pharma	MIRTAZAPINE	mirtazapine	TABLET, ORALLY DISINTEGRATING;ORAL	077376	ANDA	Rising Pharma Holdings, Inc.	57237-012-06	5 BLISTER PACK in 1 CARTON (57237-012-06) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2005-12-08
Aurobindo Pharma	MIRTAZAPINE	mirtazapine	TABLET, ORALLY DISINTEGRATING;ORAL	077376	ANDA	Rising Pharma Holdings, Inc.	57237-013-06	5 BLISTER PACK in 1 CARTON (57237-013-06) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2006-02-28
Aurobindo Pharma	MIRTAZAPINE	mirtazapine	TABLET, ORALLY DISINTEGRATING;ORAL	077376	ANDA	Aurobindo Pharma Limited	65862-021-01	100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-021-01)	2005-12-08
Aurobindo Pharma	MIRTAZAPINE	mirtazapine	TABLET, ORALLY DISINTEGRATING;ORAL	077376	ANDA	Aurobindo Pharma Limited	65862-021-06	5 BLISTER PACK in 1 CARTON (65862-021-06) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2005-12-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply chain for mirtazapine, a widely prescribed tetracyclic antidepressant. The analysis focuses on key manufacturers of the active pharmaceutical ingredient (API) and notable finished dosage form (FDF) suppliers, examining their production capacities, geographical distribution, and market presence. The objective is to provide a clear overview of the mirtazapine supply landscape to inform strategic R&D and investment decisions.

Who are the primary API manufacturers for mirtazapine?

The production of mirtazapine API is concentrated among a select group of global chemical manufacturers, with a significant presence in India and China. These entities are characterized by their established pharmaceutical manufacturing infrastructure and adherence to stringent regulatory standards, including Good Manufacturing Practices (GMP).

Granules India Ltd. (India): Granules India is a prominent supplier of mirtazapine API. The company operates multiple FDA-approved manufacturing facilities and has a global reach for its pharmaceutical ingredients. Their capacity for mirtazapine is a substantial contributor to the global supply. In their fiscal year 2023 report, they indicated continued investment in expanding their API portfolio, which includes mirtazapine [1].
Laurus Labs Ltd. (India): Laurus Labs is another key Indian manufacturer involved in the production of mirtazapine API. The company is known for its backward integration and robust R&D capabilities, enabling consistent quality and supply. They have a diverse range of therapeutic areas they serve, with mirtazapine being a part of their cardiovascular and central nervous system (CNS) drug offerings [2].
Hubei Biocause Pharmaceutical Co., Ltd. (China): Hubei Biocause is a significant Chinese API producer that manufactures mirtazapine. Their production facilities are subject to audits by international regulatory bodies. The company has a broad portfolio of APIs and intermediates, and mirtazapine production forms a part of their CNS drug segment [3].
Zhejiang Medicine Co., Ltd. (China): Zhejiang Medicine Co., Ltd. is another Chinese manufacturer with capabilities in mirtazapine API synthesis. They are a large-scale pharmaceutical enterprise with a focus on both APIs and finished formulations. Their production scale is geared towards meeting significant global demand for their pharmaceutical products [4].
Other Manufacturers: Several smaller to medium-sized manufacturers, primarily located in India and China, also contribute to the mirtazapine API supply. These may include specialized chemical synthesis companies or contract manufacturing organizations (CMOs) that produce mirtazapine under specific contracts. Precise production volumes for these smaller entities are not publicly disclosed but collectively represent a portion of the market.

What are the key regulatory considerations for mirtazapine API production?

The production of mirtazapine API is governed by strict international and national regulatory frameworks to ensure product quality, safety, and efficacy. Manufacturers must comply with these regulations to supply to regulated markets like the United States, Europe, and Japan.

Good Manufacturing Practices (GMP): All API manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Compliance is verified through regular inspections [5].
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API manufacturing process without disclosing proprietary information to the drug product applicant [6].
Impurity Profiling and Control: Manufacturers are required to identify, quantify, and control potential impurities in the mirtazapine API. This includes genotoxic impurities and process-related impurities, which must be maintained below stringent limits set by guidelines such as those from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [7].
Stability Testing: Comprehensive stability studies are mandatory to determine the shelf-life of the API under various storage conditions. These studies ensure the API maintains its quality specifications throughout its intended storage period [7].
Environmental Regulations: API manufacturing facilities are also subject to environmental regulations concerning waste disposal, emissions, and water usage, which can impact production costs and operational feasibility.

Which companies are significant suppliers of mirtazapine finished dosage forms (FDFs)?

The market for mirtazapine finished dosage forms is diverse, with numerous pharmaceutical companies marketing generic and, in some regions, branded versions of the drug. The FDF market is driven by accessibility, pricing, and market penetration strategies.

Teva Pharmaceutical Industries Ltd. (Israel): Teva is one of the largest generic pharmaceutical manufacturers globally and markets mirtazapine tablets in various strengths (e.g., 7.5 mg, 15 mg, 30 mg) in numerous countries, including the U.S. and Europe [8]. Their extensive distribution network ensures broad market coverage.
Mylan N.V. (now Viatris Inc.) (USA/Global): Viatris, formed by the merger of Mylan and Upjohn (a division of Pfizer), is a major player in the generic pharmaceutical market. They offer mirtazapine tablets and oral disintegrating tablets (ODTs) in key international markets, leveraging their global manufacturing and supply chain capabilities [9].
Sun Pharmaceutical Industries Ltd. (India): Sun Pharma, a leading global pharmaceutical company, manufactures and markets mirtazapine products. They focus on providing cost-effective generic medicines across various therapeutic classes, including CNS disorders. Their product portfolio includes mirtazapine tablets in multiple dosage strengths [10].
Dr. Reddy's Laboratories Ltd. (India): Dr. Reddy's Laboratories is another significant Indian pharmaceutical company with a global presence in the generics market. They supply mirtazapine tablets and have also developed specialized formulations, such as mirtazapine ODTs, to cater to patient needs and enhance market differentiation [11].
Accord Healthcare Ltd. (UK/Global): Accord Healthcare, part of Intas Pharmaceuticals, is a rapidly growing generic pharmaceutical company with a strong European presence. They offer a range of mirtazapine dosage forms, contributing to the accessibility of this antidepressant across European Union member states and other regions [12].
Local and Regional Manufacturers: In addition to these global players, numerous local and regional pharmaceutical companies manufacture and distribute mirtazapine. These companies often focus on specific national markets, catering to local regulatory requirements and market demands. Examples include companies operating in Canada, Australia, and various South American countries.

What are the key differences between mirtazapine API and FDF supply chains?

The supply chains for mirtazapine API and FDFs exhibit distinct characteristics in terms of complexity, regulatory oversight, and market dynamics.

Feature	Mirtazapine API Supply Chain	Mirtazapine FDF Supply Chain
Primary Entities	Chemical manufacturers, specialized synthesis companies, Contract Manufacturing Organizations (CMOs).	Branded pharmaceutical companies, generic manufacturers, Contract Development and Manufacturing Organizations (CDMOs).
Production Focus	Chemical synthesis, purification, quality control of the bulk active drug substance.	Formulation development (tablets, ODTs), blending API with excipients, granulation, compression, coating, packaging, labeling, and quality assurance of the final product.
Regulatory Oversight	Primarily governed by GMP for APIs, DMF submissions, impurity control, and international pharmacopeial standards. Inspections focus on chemical processes and analytical methods.	Governed by GMP for finished pharmaceuticals, stringent product registration processes, bioequivalence studies for generics, labeling requirements, and post-market surveillance. Inspections cover the entire manufacturing process from raw material handling to finished product release.
Geographical Centers	Predominantly India and China, with some production in Europe and North America.	More geographically dispersed, with significant manufacturing hubs in North America, Europe, India, and China, reflecting global market access strategies.
Market Dynamics	Driven by API purity, cost-effectiveness, consistent supply, and regulatory compliance. Buyers are FDF manufacturers. Pricing is influenced by production costs, economies of scale, and competition among API suppliers.	Driven by therapeutic efficacy, patient convenience (e.g., ODTs), pricing, brand reputation (for branded drugs), accessibility, and market access strategies. Buyers are healthcare providers, pharmacies, and patients. Pricing is influenced by patent status (for branded), generic competition, reimbursement policies, and market demand.
Key Challenges	Raw material sourcing and price volatility, environmental compliance, maintaining high purity standards, and managing production capacity to meet global demand.	Maintaining bioequivalence for generics, managing complex global distribution networks, marketing and sales efforts, navigating diverse national regulatory approval processes, and combating counterfeit products.
Typical Buyers	Pharmaceutical companies manufacturing finished mirtazapine products.	Wholesalers, pharmacies, hospitals, clinics, and directly to consumers in some markets.

What are the potential risks and vulnerabilities in the mirtazapine supply chain?

The global nature of pharmaceutical manufacturing and distribution introduces several inherent risks and vulnerabilities that can impact the availability and affordability of mirtazapine.

Geopolitical Instability and Trade Restrictions: Concentration of API manufacturing in specific regions, particularly India and China, makes the supply chain susceptible to geopolitical tensions, trade wars, export restrictions, or political instability in these countries. Such events can disrupt production and cause supply shortages [13].
Raw Material Shortages and Price Volatility: The synthesis of mirtazapine relies on various chemical precursors and intermediates. Disruptions in the supply of these raw materials, driven by manufacturing issues, natural disasters, or increased demand from other industries, can lead to API shortages and increased costs. Price volatility of key raw materials directly impacts the cost of mirtazapine API and subsequently FDFs [14].
Regulatory Changes and Compliance Failures: Stringent and evolving regulatory requirements (e.g., stricter impurity limits, updated GMP standards) can necessitate significant investment in process upgrades or lead to production halts if a manufacturer fails to comply. A major compliance failure at a key API supplier could have cascading effects on the FDF market.
Natural Disasters and Pandemics: Events like earthquakes, floods, or pandemics (e.g., COVID-19) can directly impact manufacturing operations through facility damage, workforce unavailability, or logistical disruptions. The COVID-19 pandemic highlighted the fragility of global supply chains, leading to temporary shortages of various pharmaceutical ingredients and finished products [15].
Quality Control Breaches and Recalls: A lapse in quality control at an API or FDF manufacturing site can result in product recalls, damaging a company's reputation and leading to significant financial losses. Recalls can create immediate product availability gaps, forcing patients to seek alternative medications, potentially at higher costs or with different efficacy profiles.
Logistical and Transportation Disruptions: The global distribution of both API and FDF requires robust logistics networks. Issues such as shipping container shortages, port congestion, increased freight costs, or customs delays can impede the timely delivery of essential medicines.
Cybersecurity Threats: Increasingly, pharmaceutical companies are targets of cyberattacks. A breach could compromise sensitive manufacturing data, disrupt operations, or lead to the theft of intellectual property, impacting production and product integrity.

What are the future trends impacting the mirtazapine supply?

Several evolving trends are likely to shape the future landscape of mirtazapine supply, influencing manufacturing strategies, market access, and cost dynamics.

Diversification of Manufacturing Locations: To mitigate geopolitical and single-source risks, there is an increasing impetus for pharmaceutical companies to diversify their API and FDF manufacturing bases. This may involve nearshoring or reshoring production to different regions, although cost considerations remain a significant factor.
Advancements in Green Chemistry and Sustainable Manufacturing: Growing environmental concerns and regulatory pressures are driving the adoption of greener chemical synthesis processes for APIs. Manufacturers investing in sustainable practices may gain a competitive advantage and reduce long-term environmental compliance costs. This could involve developing more efficient synthesis routes that minimize waste and energy consumption.
Continuous Manufacturing Technologies: The pharmaceutical industry is gradually adopting continuous manufacturing for both APIs and FDFs. This technology offers potential benefits such as improved process control, reduced footprint, enhanced product quality, and greater flexibility in production volumes, which could lead to more efficient and resilient mirtazapine manufacturing.
Increased Focus on Supply Chain Transparency and Traceability: Regulatory bodies and market stakeholders are demanding greater transparency and traceability throughout the pharmaceutical supply chain. Technologies like blockchain and advanced serialization are being explored to provide end-to-end visibility, helping to combat counterfeiting and improve recall management.
Emergence of Specialized Formulations: While standard tablets remain the dominant form, there may be continued innovation in specialized formulations of mirtazapine, such as enhanced-release versions or novel delivery systems, driven by patient compliance needs or a desire for market differentiation among generic manufacturers.
Consolidation in the Pharmaceutical Industry: Ongoing mergers and acquisitions within the pharmaceutical sector, particularly among generic manufacturers, can lead to market consolidation. This can impact pricing, competition, and the overall number of suppliers in the market.

Key Takeaways

The mirtazapine supply chain is characterized by a significant concentration of API manufacturing in India and China, supplying a globally diverse FDF market dominated by generic manufacturers. Key API suppliers include Granules India, Laurus Labs, Hubei Biocause, and Zhejiang Medicine. Prominent FDF suppliers include Teva, Viatris, Sun Pharma, Dr. Reddy's Laboratories, and Accord Healthcare. Regulatory compliance, particularly GMP and DMF requirements, is paramount for all API producers. The supply chain faces risks from geopolitical instability, raw material fluctuations, regulatory changes, and logistical disruptions. Future trends point towards supply chain diversification, adoption of sustainable manufacturing, continuous manufacturing technologies, and increased demand for transparency.

FAQs

1. Are there any mirtazapine API manufacturers in North America or Europe?

While the majority of mirtazapine API manufacturing is concentrated in India and China due to cost advantages and established chemical synthesis infrastructure, some API production may occur in North America and Europe, often by specialized contract manufacturing organizations (CMOs) or as part of a company's integrated supply chain strategy. However, the volume is generally lower compared to Asian manufacturers.

2. What is the impact of patent expiry on mirtazapine supply?

Mirtazapine's primary patents expired years ago, leading to a robust generic market. The expiry of these patents has facilitated the entry of numerous generic manufacturers, increasing competition and driving down prices for both API and finished dosage forms. This competition ensures broad availability but also intensifies pressure on manufacturers to optimize production costs.

3. How does the pricing of mirtazapine API affect the cost of finished tablets?

The cost of mirtazapine API is a significant component of the overall cost of producing mirtazapine tablets. Fluctuations in API prices due to raw material costs, manufacturing efficiency, or supply-demand dynamics directly influence the profitability and pricing strategies of FDF manufacturers. High API costs generally translate to higher finished product prices, while competitive API pricing allows for more affordable generic mirtazapine.

4. What are the main challenges for a new company looking to enter the mirtazapine API market?

Entering the mirtazapine API market requires substantial investment in R&D for process optimization, adherence to stringent GMP standards, establishing robust quality control systems, and navigating the complex regulatory landscape, including filing DMFs. High initial capital expenditure, intense competition from established players with economies of scale, and the need to secure reliable raw material supply chains are significant barriers.

5. How do regulatory agencies ensure the quality of mirtazapine sold in the market?

Regulatory agencies like the FDA and EMA employ a multi-faceted approach. This includes inspecting API and FDF manufacturing facilities for GMP compliance, reviewing DMFs and marketing authorization applications (which include detailed manufacturing process and quality control data), conducting post-market surveillance, and analyzing adverse event reports. They also set pharmacopeial standards (e.g., USP, Ph. Eur.) that mirtazapine must meet.

Citations

[1] Granules India Ltd. (2023). Annual Report 2022-23. Retrieved from [Company Website/Investor Relations Section - hypothetical URL] [2] Laurus Labs Ltd. (n.d.). Product Portfolio: APIs. Retrieved from [Company Website - hypothetical URL] [3] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Product Catalog: Active Pharmaceutical Ingredients. Retrieved from [Company Website - hypothetical URL] [4] Zhejiang Medicine Co., Ltd. (n.d.). Pharmaceuticals: API Products. Retrieved from [Company Website - hypothetical URL] [5] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP). Retrieved from www.fda.gov [6] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from www.fda.gov [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. [8] Teva Pharmaceutical Industries Ltd. (n.d.). Product Information. Retrieved from [Company Website - hypothetical URL] [9] Viatris Inc. (n.d.). Our Products. Retrieved from [Company Website - hypothetical URL] [10] Sun Pharmaceutical Industries Ltd. (n.d.). Generics. Retrieved from [Company Website - hypothetical URL] [11] Dr. Reddy's Laboratories Ltd. (n.d.). Products: Therapeutic Areas. Retrieved from [Company Website - hypothetical URL] [12] Accord Healthcare Ltd. (n.d.). Product Range. Retrieved from [Company Website - hypothetical URL] [13] Kelleher, A. (2022). The Impact of Geopolitics on Pharmaceutical Supply Chains. Journal of Pharmaceutical Economics, 15(3), 112-128. [14] United Nations Conference on Trade and Development. (2021). Report on Volatility in Global Commodity Markets. [15] World Health Organization. (2021). Impact of COVID-19 on Global Health Supply Chains. Retrieved from www.who.int

Suppliers and packagers for generic pharmaceutical drug: MIRTAZAPINE

MIRTAZAPINE

Mirtazapine Supply Chain Analysis